

Info Sheet for Technical description

No. 0008

Organization

* Mandatory fields

Name of Organization*	Metcela Inc.		
Address, City, States, Zip, Country*	Life Innovation Center 3-25-22 Tonomachi, Kawasaki-ku, Kawasaki-shi, Kanagawa, Japan 210-0821		
URL	https://www.metcela.com/en/		
Brief Descriptions of Organization* (Approx. 100 words)	Metcela Inc. is a clinical-stage biotech startup based in Japan. At Metcela, we are developing cardiac stem cell-based therapy for diseases with that currently have limited therapeutic options. One of our lead pipeline, JRM-001, is autologous cardiac stem cell product for rare pediatric congenital heart disease. It was designated the Sakigake and Orphan designation by the Japanese government. JRM-001 is currently in Phase 3 randomized, controlled, multicenter trial in Japan.		
Contact address	Name*	Aiko SUGE	
	Department* / Position	COO, Director	
	E-mail* / TEL	cd@metcela.com	

What kind of technology do you want to offer? *

- ☒ **A.** Clinical Development Pipelines → Please see **Sheet [A]**
- ☐ **B.** Regenerative Medicine-related Consumables / Instruments / Materials / CDMO Services etc. → Please see **Sheet [B]**
- ☐ **C.** Platform Technologies(*) that are not included in the above (Group B) → Please see **Sheet [C]**
- * Peripheral technologies that contribute to a significant improvement in productivity throughout the value chain of pharmaceuticals, from research and development to manufacturing and ultimately market launch.

If you agree to the following, please check "Yes" below. *

The technologies introduced in this 'Info Sheet' are in the public domain, as they have been published in research papers or have related patent applications.

- ☒ Yes

Do you have any collaborations/partnerships with pharmaceutical companies?

- ☐ Yes
- ☒ No

If you have already received funding from VCs or other sources, up to which stage has the investment round progressed?

- ☐ Angel / Seed (including AMED/JST grants)
- ☐ Series A
- ☐ Series B
- ☒ Series C
- ☐ Series D or further advanced stages

Do you agree to leave your presentation materials at FIRM hands and entrust us to make use of them for the purpose of promoting your partnering opportunities? *

Options*	Comments
☒ Yes	
☐ No	

Filled in by*

Date*

Aiko SUGE, COO, Metcela Inc.

2025.08.29

Sheet [A] Clinical Development Pipelines**Info Sheet for Technical overview**

No. A-0008

* Mandatoty fields

Title***JRM-001: Autologus Cell Therapy for Pediatric Orphan Heart Desease****Development Phase***

- | | | |
|---|--|--|
| ☐ Basic Research | ☐ Drug Discovery | ☐ Pre-Clinical |
| ☐ Clinical Trial (Phase I) | ☐ Clinical Trial (Phase II) | ☒ Clinical Trial (Phase III) |
| ☐ Review | ☐ Others | |

Diesease Area*

- | | | |
|--|---|--|
| ☐ Cancer | ☐ Central nervous system | ☐ Ophthalmology |
| ☐ Musculoskeletal | ☐ Endocrine / Metabolism | ☒ Cardiovascular |
| ☐ Urogenital | ☐ Digestive organ | ☐ Blood |
| ☐ Infection | ☐ Dermatology | ☐ Immunity |
| ☐ Otolarngology | ☐ Respiratory | ☐ Others |

Description*

Metcela Inc. is a clinical-stage biotech startup based in Japan. At Metcela, we are developing cardiac stem cell-based therapy for diseases with that currently have limited therapeutic options.

One of our lead pipeline, JRM-001, is autologous cardiac stem cell product for rare pediatric congenital heart disease. It was designated the Sakigake and Orphan designation by the Japanese government. JRM-001 is currently in Phase 3 randomized, controlled, multicenter trial in Japan.

Filled in by*

Aiko SUGE, COO, Metcela Inc.

Date*

2025.08.29

Info Sheet for Technical description

No. 0008

Organization

* Mandatory fields

Name of Organization*	Metcela Inc.		
Address, City, States, Zip, Country*	Life Innovation Center 3-25-22 Tonomachi, Kawasaki-ku, Kawasaki-shi, Kanagawa, Japan 210-0821		
URL	https://www.metcela.com/en/		
Brief Descriptions of Organization* (Approx. 100 words)	Metcela Inc. is a clinical-stage biotech startup based in Japan. At Metcela, we are developing cardiac stem cell-based therapy for diseases with that currently have limited therapeutic options. One of our lead pipeline, JRM-001, is autologous cardiac stem cell product for rare pediatric congenital heart disease. It was designated the Sakigake and Orphan designation by the Japanese government. JRM-001 is currently in Phase 3 randomized, controlled, multicenter trial in Japan.		
Contact address	Name*	Aiko SUGE	
	Department* / Position	COO, Director	
	E-mail* / TEL	cd@metcela.com	

What kind of technology do you want to offer? *

- ☒ **A.** Clinical Development Pipelines → Please see **Sheet [A]**
- ☐ **B.** Regenerative Medicine-related Consumables / Instruments / Materials / CDMO Services etc. → Please see **Sheet [B]**
- ☐ **C.** Platform Technologies(*) that are not included in the above (Group B) → Please see **Sheet [C]**
- * Peripheral technologies that contribute to a significant improvement in productivity throughout the value chain of pharmaceuticals, from research and development to manufacturing and ultimately market launch.

If you agree to the following, please check "Yes" below. *

The technologies introduced in this 'Info Sheet' are in the public domain, as they have been published in research papers or have related patent applications.

- ☒ Yes

Do you have any collaborations/partnerships with pharmaceutical companies?

- ☐ Yes
- ☒ No

If you have already received funding from VCs or other sources, up to which stage has the investment round progressed?

- ☐ Angel / Seed (including AMED/JST grants)
- ☐ Series A
- ☐ Series B
- ☒ Series C
- ☐ Series D or further advanced stages

Do you agree to leave your presentation materials at FIRM hands and entrust us to make use of them for the purpose of promoting your partnering opportunities? *

Options*	Comments
☒ Yes	
☐ No	

Filled in by*

Date*

Aiko SUGE, COO, Metcela Inc.

2025.08.29